TaBlitz

𝐉𝐨𝐢𝐧 𝐃𝐫. 𝐓𝐚𝐁𝐥𝐢𝐭𝐳 𝐋𝐢𝐯𝐞 𝐓𝐨𝐦𝐨𝐨𝐫𝐫𝐨𝐰!

Every month, we take one real formulation or production problem—sticking, picking, capping, lamination, scale-up breakdowns—and open it up.

𝘙𝘦𝘢𝘭 𝘧𝘰𝘰𝘵𝘢𝘨𝘦. 𝘙𝘦𝘢𝘭 𝘢𝘯𝘢𝘭𝘺𝘴𝘪𝘴. 𝘙𝘦𝘢𝘭 𝘢𝘯𝘴𝘸𝘦𝘳𝘴.

You’ll see what’s happening inside and outside the tablet press during compaction.
You’ll watch live TaBlitz demos tracing root cause in real time.
And you’ll hear expert insight connecting what’s happening on press to why it’s happening in your formulation.

We close every session with live Q&A—bring the question that’s been holding your batch back and get a direct answer.

🚨 1 day away — don’t miss it

Join Pharma Excipients, all4nutra.com, Dr. TaBlitz, and Natoli Scientific

𝗗𝗿. 𝗧𝗮𝗯𝗹𝗶𝘁𝘇 𝗟𝗶𝘃𝗲 𝗦𝗲𝘀𝘀𝗶𝗼𝗻𝘀
📅 Tuesday, Apr. 14, 2026
⏰ 10:00 AM EDT | 4:00 PM CET

Streaming live on YouTube and LinkedIn.

👉 Set your reminder and subscribe so you don’t miss it:
https://lnkd.in/erQGPcQH

𝐕𝐢𝐫𝐭𝐮𝐚𝐥 𝐃𝐫𝐮𝐠 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐚𝐫𝐞 𝐛𝐮𝐢𝐥𝐭 𝐭𝐨 𝐨𝐩𝐞𝐫𝐚𝐭𝐞 𝐥𝐞𝐚𝐧.
But lean should never mean blind.

When you don’t own manufacturing, your leverage comes from clarity.

Clarity on your formulation.
Clarity on your risks.
Clarity on what will — and won’t — scale.

That’s where TaBlitz changes the equation.

We help VDCs move forward with:

✅ Early, material-sparing insight
✅ Physics-based formulation confidence
✅ Predictive robustness before scale-up
✅ A stronger technical position with CDMOs
✅ A cleaner, more defensible narrative for regulators and investors

This isn’t incremental value.

It’s structural risk reduction.

If you’re building lean, build informed.

Let’s talk. Demo here: https://lnkd.in/gHQCv72d

𝐌𝐨𝐬𝐭 𝐭𝐚𝐛𝐥𝐞𝐭 𝐟𝐚𝐢𝐥𝐮𝐫𝐞𝐬 𝐚𝐫𝐞𝐧’𝐭 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐞𝐝 𝐢𝐧 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭.
𝐓𝐡𝐞𝐲’𝐫𝐞 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐞𝐝 𝐚𝐭 𝐭𝐡𝐞 𝐰𝐨𝐫𝐬𝐭 𝐩𝐨𝐬𝐬𝐢𝐛𝐥𝐞 𝐦𝐨𝐦𝐞𝐧𝐭.

Traditionally, failure modes show up in one of three painful ways:

🔹 During the first engineering or exhibit batch — when confidence is high and timelines are tight.
🔹 During PPQ — the most expensive moment to learn something new about your formulation.
🔹 After approval — when a new raw material lot or seasonal humidity shift quietly pushes the process outside its undocumented limits.

By the time these issues appear, the formulation is locked, the validation plan is active, and the cost of adjustment is measured in weeks — not hours.

𝐖𝐡𝐚𝐭 𝐦𝐚𝐤𝐞𝐬 𝐭𝐡𝐢𝐬 𝐞𝐬𝐩𝐞𝐜𝐢𝐚𝐥𝐥𝐲 𝐟𝐫𝐮𝐬𝐭𝐫𝐚𝐭𝐢𝐧𝐠?

In most cases, the failure wasn’t random.
It was hiding in the physics — in the micromeritics, the compaction limits, the strain-rate sensitivity, the geometry stress distribution.

It just wasn’t evaluated early enough.

The strongest teams are no longer asking,
“Did it pass?”

They’re asking,
“Where are the edges — and have we tested them?”

Because robustness isn’t proven at the center of the design space.
It’s proven at the boundaries.

And discovering those boundaries during PPQ is not a strategy — it’s a gamble.

👉 If you want to identify your formulation’s edges before engineering batches, PPQ, or post-approval variability does it for you, let’s talk.
Schedule a demo and see how predictive robustness changes the way you approach scale-up.

Schedule your demo here: https://lnkd.in/gA2SrvjS